Abstract
Studies of male breast cancer are rare in Africa. In Togo in particular, no work has focused on the epidemiological, mammo-echographic, pathological, therapeutic or prognostic aspects of male breast cancer. The aim of this study is to report cases of male breast cancer in Togo by describing the main epidemiological, mammo-echographic and pathological aspects. This was a retrospective, descriptive and analytical study of 10 cases of male patients presenting with breast cancer confirmed by the pathologic examination on the echo-guided samples over a period of 6 years in University Teaching Hospital in Lome. A total of ten patients were retained. The mean age of patients was 55 years with extremes of 39 years and 65 years. All patients had a palpable breast mass. The lesions were classified in 60% American College of Radiology (ACR) 5 and 40% ACR 4. The axillary lymph node invasion rate was 40%. Infiltrating ductal carcinoma was the histologic type diagnosed in all patients. Any breast mass in an elderly male subject is suspected with high predictive value. Mammography ultrasound plays an important role in the diagnosis alongside pathology.
Highlights
Studies of male breast cancer are rare in Africa
The aim of this study is to report cases of male breast cancer in Togo by describing the main epidemiological, mammo-echographic and pathological aspects
There are 2000 new cases of male breast cancer diagnosed each year in the United States in a recent study published in May 2017 [2]
Summary
There are 2000 new cases of male breast cancer diagnosed each year in the United States in a recent study published in May 2017 [2]. In Africa where it was long ignored, male breast cancer, is characterized by a late diagnosis [3]. Recent studies in Morocco and Nigeria has shown that the disease is present in Africa as well as in developed countries because of longer life expectancy and better accessibility to screening and treatment facilities. This disease was very deadly in Africa [4] [5]. The treatment includes alone or in combination, chemotherapy, radiotherapy, surgery and hormone therapy depending on the stage of the disease and the immunohistochemical type
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
